Abstract 333P
Background
FDG-PET/CT and Thallium SPECT (TL) which are radioisotope examination are inspection used as diagnostic imaging in the malignant tumors conventionally, and it is reported when useful for a stage diagnosis of the lung cancer. It was common to use the CT imaging according to the RECIST criteria for the effect judgment of cytotoxic agents and molecular target agents. In determining the efficacy of immune checkpoint inhibitors (ICIs), we often experienced that the assessment on CT imaging and the true effect do not match. Therefore, we planned a prospective study to evaluate whether FDG-PET/CT and TL examination is useful for ICI effect judgment. We examined the correlation between SUV differences on PET examination before treatment and 2 months after treatment initiation and RECIST evaluation.
Methods
A total of 18 advanced NSCLC patients treated at Kansai Medical University Hospital from September 2017 to September 2018 using ICI monotherapy were enrolled in this study. We examined the correlation with a PERCIST response rate and the response rate that went to the CT evaluation using RECIST1.1.
Results
The median age was 74 years. There were 15 men and three women. 15 cases were evaluable both before and two months after treatment initiatoin. There were CR/PR/SD/PD;0/3/7/5 by RECIST evaluation, and the curative effect judgment by FDG-PET were CMR/PMR/SMD/PMD; 1/3/6/5. 1 case was PD in RECIST, but was PMR in FDG-PET.The PR case tended to be higher in Tl accumulation after the treatment than an SD and PD cases.
Conclusions
The effect measurement by FDG-PET showed usefulness with more than that of RECIST evaluation and Tl-SPECT seems to have the potential to be useful in determining the effect of ICIs.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Takayasu Kurata.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
154P - Genetic characteristics of participants in the Australian Pancreatic Screening Study
Presenter: Krithika Murali
Session: Poster display session
Resources:
Abstract
155P - Mean Platelet Volume (MPV) is it a new prognostic marker in resectable carcinoma stomach?
Presenter: Girish M. S
Session: Poster display session
Resources:
Abstract
156P - A positive feedback between IDO1 metabolite and COL12A1 via MAPK pathway to promote gastric cancer metastasis
Presenter: Zhen Xiang
Session: Poster display session
Resources:
Abstract
157P - Lymph node ratio (LNR) a better prognostic factor after D2 gastrectomy
Presenter: Jitin Yadav
Session: Poster display session
Resources:
Abstract
158P - A clinical significance of preoperative C-reactive protein/albumin ratio in patients with extrahepatic bile duct cancer
Presenter: Kim Jinkook
Session: Poster display session
Resources:
Abstract
159P - The relation between obesity and cancer of gastrointestinal tract in Korea: The data from Statistic Korea between 2001 and 2016
Presenter: Hee Man Kim
Session: Poster display session
Resources:
Abstract
160P - Clinical outcomes of second-line chemotherapy after progression on nab-paclitaxel plus gemcitabine in patients with metastatic pancreatic adenocarcinoma
Presenter: Jooyoung Ha
Session: Poster display session
Resources:
Abstract
161P - Chitinase 3-Like 1 gene (T/C) polymorphism and serum YKL-40 in hepatocellular carcinoma
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
162P - Hypofractionated radiotherapy for pulmonary metastases from hepatocellular carcinoma: Treatment response and prognostic factors affecting survival
Presenter: In Young Jo
Session: Poster display session
Resources:
Abstract
163P - Excision repair cross-complementation group 1 and 2 (ERCC1/2) Single nucleotide polymorphisms and chemotherapy treatment outcome in Cholangiocarcinoma
Presenter: Thanachai Sanlung
Session: Poster display session
Resources:
Abstract